- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02011685
Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors
February 17, 2022 updated by: NYU Langone Health
This study will assess the comparative effectiveness, cost-effectiveness and sustainability of two telemonitoring interventions in reducing blood pressure and recurrent stroke among 450 high-risk Black and Hispanic stroke patients.
The primary hypothesis is that home blood pressure telemonitoring supplemented with individualized, culturally tailored telephone-based nurse case management will have greater effects on blood pressure reduction and stroke recurrence and, while it will be more costly, it will also be more cost-effective than home blood pressure telemonitoring alone.
Results of this study will provide strong empirical evidence to inform clinical guidelines and practice, which may lead to reductions in stroke disparities in the United States.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
450
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Black or Hispanic
- Age 18 years or older
- English or Spanish speaking
- Patients who have had an ischemic or hemorrhagic stroke
- Modified Rankin scale score of ≤ 3
- Average screening SBP ≥ 140 mm Hg from three BP readings taken at two separate visits with a validated automated device
- Receiving care at the study site for at least 6 months and planning to continue receiving care at the site for the next two years.
Exclusion Criteria:
- Being deemed unable to comply with the study protocol (either self-selected or by indicating during screening that he/she could not complete all requested tasks including using the HBPTM or interacting with the NCM if he/she were to be randomized to the intervention group)
- Participation in other clinical trials
- Diagnosis of cognitive dysfunction or significant psychiatric comorbidity (as indicated in medical record)
- Patients with upper arm circumference ≥ 52 cm, the maximum limit of the extra-large BP cuff
- Diagnosis of dialysis or end stage renal disease
- Relocating out of area or extended travel during study period
- Significant verbal speech impairment; unable to participate in intervention telephone sessions
- Pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Home BP Telemonitoring (HBPTM)
Participants will take home BP readings 3 days per week (morning and evening) for one week out of each month during the 12-month intervention.
|
Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months.
BP readings will be transmitted wirelessly to a secure server.
Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.
|
Experimental: HBPTM + Nurse Case Management (NCM)
Participants will complete the same Home BP Telemonitoring protocol and will also complete 20 counseling phone calls with a nurse case manager during the 12-month intervention.
|
Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months.
BP readings will be transmitted wirelessly to a secure server.
Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.
Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12.
The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication.
They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques.
Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation.
NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
12-month systolic blood pressure (SBP) change
Time Frame: Baseline, 12 months
|
Baseline, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
24-month stroke recurrence
Time Frame: 24 months
|
24 months
|
Cost-effectiveness for reducing SBP at 12 months
Time Frame: 12 months
|
12 months
|
Cost-effectiveness for reducing stroke recurrence at 24 months
Time Frame: 24 Months
|
24 Months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in other stroke risk factors
Time Frame: 6, 12, 24 months
|
lipids, blood glucose
|
6, 12, 24 months
|
Change in health behaviors
Time Frame: 6, 12, 24 months
|
diet, physical activity, medication adherence, weight loss
|
6, 12, 24 months
|
Antihypertensive medication intensification
Time Frame: 6, 12, 24 months
|
adding, changing dose, or changing class of medications
|
6, 12, 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 18, 2014
Primary Completion (Actual)
November 30, 2019
Study Completion (Actual)
December 31, 2019
Study Registration Dates
First Submitted
December 10, 2013
First Submitted That Met QC Criteria
December 10, 2013
First Posted (Estimate)
December 13, 2013
Study Record Updates
Last Update Posted (Actual)
February 18, 2022
Last Update Submitted That Met QC Criteria
February 17, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-00281
- U54NS081765-5162 (Other Identifier: National Institute of Neurological Disorders and Stroke (NINDS))
- U54NS081765 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on Home BP Telemonitoring (HBPTM)
-
US Department of Veterans AffairsCompleted
-
University of AlbertaRecruiting
-
Universidad de la RepublicaHospital Italiano de Buenos Aires; KU LeuvenWithdrawn
-
Chang Hee, LeePurdue University; LG Electronics Inc.CompletedHypertensionKorea, Republic of
-
Shanghai Institute of HypertensionRecruiting
-
University of British ColumbiaUnknown
-
Universidad Nacional de TucumanCompleted
-
Universidad Nacional de TucumanCompleted
-
University Hospital of North NorwayUnknownCongestive Heart FailureNorway
-
Taipei Veterans General Hospital, TaiwanUnknown